Abstract
Detecting and characterizing blood clots (hematomas) in dogs is crucial for timely treatment. This review explores the potential of low-field magnetic resonance imaging (MRI) in assessing time-dependent changes in canine blood clots. We analyze a key study evaluating signal intensity variations in blood samples at different time points. While limitations exist, the findings suggest that low-field MRI may offer valuable insights into clot development and age estimation, potentially aiding diagnosis and treatment planning.
Introduction
Blood clots, or hematomas, can occur in dogs due to injuries, surgeries, or underlying health conditions. Prompt diagnosis and management are crucial to prevent complications. Conventional diagnostic tools like X-rays and ultrasounds have limitations in characterizing blood clots. Magnetic resonance imaging (MRI) offers a more detailed view but often requires high-field strength magnets, making it expensive and less accessible in veterinary settings. Low-field MRI presents a potential alternative. This review examines a study investigating the use of low-field MRI to assess time-dependent changes in canine blood clots, offering insights into its diagnostic potential.
Time-Dependent Signal Intensity and Clot Characterization
The study by Jeong et al. (2015) [1] evaluated the signal intensity of canine blood clots in low-field MRI scans over 30 days. Blood samples from healthy dogs were analyzed, revealing distinct changes in signal intensity based on clot composition and age. Heterogeneous clots, likely containing a mix of cellular components and fluids, displayed layered structures with varying intensity on MRI. These layers remained relatively stable after day 13, suggesting the potential for identifying older clots. The margination (border) of the clot and surrounding plasma also showed significant changes over time.
Limitations and Future Directions
Despite the promising findings, the study highlights limitations. The in vitro nature of the experiment doesn't account for the complexities of in vivo blood flow and clot formation. Accurately translating signal intensity changes to specific clot age requires further investigation. Future research needs to explore how low-field MRI performs in diagnosing and differentiating blood clots in live animals compared to traditional methods.
Conclusion
This review sheds light on the potential of low-field MRI for assessing time-dependent characteristics of canine blood clots. The study by Jeong et al. (2015) [1] provides a valuable starting point, suggesting that low-field MRI may offer insights into clot development and age estimation, potentially aiding in canine hematoma diagnosis and treatment planning. Further research is necessary to validate these findings in vivo and explore the full clinical utility of low-field MRI in veterinary medicine.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Photoacoustic spectral analysis for gaining knowledge of the tumor microenvironment.
2.
Why are so many young adults getting cancer?
3.
Scream, It's Good for You; Release the Cancer Pigeons; Talk of Chemo Rationing
4.
Blood tests can predict the risk of relapse after a bone marrow transplant in patients with acute myeloid leukemia.
5.
'Sugar' signatures help identify and classify pancreatic cancer cell subtypes
1.
Comprehensive Standards in Oncology for Modern Medicine
2.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
3.
Unveiling Canine Blood Clots Over Time: A Look at Low-Field MRI's Diagnostic Potential
4.
Understanding Phyllodes Tumor: Symptoms, Diagnosis, and Treatment Options
5.
Managing Delayed Toxicities of Targeted Anticancer Therapies
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
1.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
3.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
5.
Navigating the Complexities of Ph Negative ALL - Part XI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation